Accelerating Biosimilar Development: A Key Move by the FDA

On October 29, 2025, the FDA announced that it is taking major steps to make it faster and less costly to develop biosimilar medicines—the lower-cost alternatives to biologic drugs that treat many serious and chronic diseases. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Specifically, the agency released a draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” U.S. Food and Drug Administration+1
The guidance proposes that, in many cases, developers of biosimilars no longer need to conduct large comparative human efficacy trials (which are time-consuming and expensive), but can instead rely more on analytical and other testing. U.S. Food and Drug Administration+1
In addition, the FDA indicated it plans to make it easier for biosimilars to be developed and approved as interchangeable with the original biologic products—meaning that pharmacists may more easily substitute them for the branded version. U.S. Food and Drug Administration+1

The aim: to expand competition in the biologic drug market, improve access to lower‐cost options, and reduce drug costs for patients and the healthcare system. U.S. Food and Drug Administration

---

Why This Was Necessary

1. Disproportionate cost burden from biologics

Although biologic medications (drugs derived from living organisms or complex biologic manufacturing) account for only about 5% of prescriptions in the U.S., they represent about 51% of total drug spending as of 2024. U.S. Food and Drug Administration+1
That disparity means that a small number of very expensive biologics are imposing a heavy cost burden.

2. Slow uptake and limited development of biosimilars

Despite the price burden of biologics, uptake of biosimilars (and their development) has been limited: the FDA has approved 76 biosimilars to date—still only a small fraction of all biologics. U.S. Food and Drug Administration+1
Only around 10% of biologic drugs expected to lose patent protection in the next decade currently have a biosimilar in development. U.S. Food and Drug Administration+1
A recent report found that although biosimilars saved U.S. healthcare more than US$12 billion in 2023, and US$36 billion since first entry, uptake and development remain constrained. Accessible Meds

3. High cost and duration of development

Biosimilar development has been burdened by expensive and time‐consuming requirements (e.g., large human clinical trials, “switching studies” for interchangeability). The FDA notes that comparative efficacy studies “generally have low sensitivity compared to many other analytical assessments,” and that they may require 1-3 years and cost on average about US$24 million. U.S. Food and Drug Administration
These kinds of hurdles discourage entry into the biosimilar market, which limits competition and keeps prices high.

4. Gaps in access and cost pressures

High drug costs (especially biologics) lead to patient access issues: treatment abandonment, dose‐skipping, or patients foregoing necessary therapy. The HHS fact sheet points this out directly. HHS.gov
Given that biologics often treat cancers, autoimmune diseases, rare disorders, the stakes are high.

So, the FDA judged that to achieve meaningful cost reductions and better access, the regulatory pathway needed updating.

---

What the Decision Entails: Key Elements & Implications

Here are the main features of the FDA’s reform plus what they imply.

Draft Guidance: Limiting Comparative Efficacy Studies

• The new draft guidance allows biosimilar sponsors to rely more heavily on analytical testing (structure, function, pharmacokinetics/pharmacodynamics) rather than defaulting to large human comparative efficacy trials. U.S. Food and Drug Administration+1
• The agency also indicates that, in many cases, “switching studies” (where patients switch back and forth between reference biologic and biosimilar) will generally not be recommended. U.S. Food and Drug Administration
• These changes are expected to reduce time and cost of development significantly—one industry commentary estimated the five-to-eight-year timeline can be cut significantly, and development cost perhaps halved. Fierce Pharma

Interchangeability Ease

• The FDA is aiming to make it easier for biosimilars to be designated as interchangeable with the reference biologic. This matters because interchangeability means a pharmacist may substitute the biosimilar for the reference product without prescriber intervention (subject to state pharmacy laws). Fierce Pharma+1
• Easier interchangeability should improve uptake of biosimilars, increasing competition and thus potentially lowering price more quickly.

Encouraging Market Entry & Competition

• By lowering regulatory barriers and reducing cost/time to market, the hope is more biosimilar developers will enter, more biologics will face biosimilar competition, and thus more options and downward pressure on costs.
• The FDA explicitly frames this initiative as advancing its mission to “make America healthy again” by expanding patient options and lowering costs. U.S. Food and Drug Administration
• A fact sheet from the Department of Health & Human Services (HHS) emphasizes that biosimilars have the promise to improve access and reduce costs, but their full potential has not yet been realised. HHS.gov

Limitations and Process

• It’s important to note this is a draft guidance—and final guidance may differ. Industry stakeholders and the public have an opportunity to comment. U.S. Food and Drug Administration+1
• The guidance remains non-binding, meaning the FDA sets out its thinking, but each biosimilar application will still be evaluated individually.
• Uptake of biosimilars depends not only on regulatory approval, but on factors such as payer coverage, physician comfort, pharmacy substitution laws, market incentives (including rebates, incentives of brand manufacturers and pharmacy benefit managers (PBMs)). The HHS fact sheet and other reports highlight these barriers. HHS.gov+1

---

Why This Matters—Especially for the Healthcare Ecosystem

For Patients

• It may mean faster access to biosimilar versions of biologics, which can be substantially cheaper than the branded biologic treatments.
• Increased availability of biosimilars can expand treatment options (particularly for chronic conditions, autoimmune disease, cancer) and reduce financial barriers.
• Lower drug cost burden may lead to improved adherence (patients less likely to skip doses or abandon treatment).

For Healthcare Payers & Systems

• With biologics accounting for a large share of drug spending (despite small prescription volume), increasing biosimilar competition offers a way to contain costs in a major segment.
• For insurers, government payers (Medicare/Medicaid), hospitals—this regulatory shift could translate into budget relief and more sustainable access.

For Pharma & Industry

• Biologic manufacturers might face increased competition earlier or more broadly—but that may also stimulate innovation.
• Biosimilar developers may find a more favourable regulatory environment (lower cost/time) and thus higher ROI potential—this could attract more entrants, boosting competition.

For Markets & Global Implications

• The U.S. has lagged Europe in biosimilar approvals and uptake. This move may help close that gap. Fierce Pharma
• The shift could influence global biosimilar markets, manufacturing, pricing and access strategies.